Evidence map›Paper›PMID 39507973›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2024

[Clinical Value of Dual Tracer PET Imaging With

Hongyuan Dai, Shuhui Huang, Tian Tian, Naifeng Hou, Hao Zeng, Qiang Wei, Rui Huang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Design, Synthesis, and Efficacy Evaluation of a Novel BRD4/HDAC Dual-Target Small-Molecule Inhibitor in Prostate Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  3. Head-to-head comparison ofFrontiers in oncology · 2025
    Article
  4. Multimodal integration of [Frontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongyuan Dai（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Shuhui Huang（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Tian Tian（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Naifeng Hou（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Hao Zeng（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Qiang Wei（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Rui Huang（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT ( Results: A total of 26 patients (63.4%) were diagnosed with metastatic castration-resistant prostate cancer (mCRPC), and 38 cases (92.7%) had a Gleason score of 8-9. Bone metastasis, the predominant type of distant metastasis, occurred in 36 cases (87.8%). The skeletal and distant lymph node metastases mostly showed a dual positive uptake pattern for both PSMA and FDG (85.7% [24/28] and 81.8% [9/11]). 37.5% (3/8) of the metastases to organs showed FDG only positive uptake pattern. The serum levels of prostate specific antigen (PSA) in group A were significantly higher than those in group B ( Conclusion: Dual-tracer PET/CT imaging with

Indexed as

Fluorodeoxyglucose F18Gallium IsotopesGallium RadioisotopesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedEdetic AcidHumansMaleMiddle AgedNeoplasm MetastasisProstate-Specific AntigenRadiopharmaceuticalsRetrospective StudiesEdetic AcidFluorodeoxyglucose F18gallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesProstate-Specific AntigenRadiopharmaceuticals18F-FDG68Ga-PSMAHeterogeneityMetastatic prostate cancer

Identifiers

PMID39507973
PMCPMC11536228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.